CPG
ITCI

Cornerstone Planning Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cornerstone Planning Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7
Closed -$890 – 1707
2024
Q4 		$890 Buy
+7
New +$575 ﹤0.01% 980
2023
Q3 		– Sell
-19
Closed -$1.2K – 1311
2023
Q2 		$1.2K Buy
+19
New +$1.18K ﹤0.01% 1305
2022
Q4 		$908 Buy
+19
New +$952 ﹤0.01% 1377

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Cornerstone Planning Group's ITCI Position: Q1 2025 in Review

Cornerstone Planning Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 7 shares — an estimated $890 sold.

Cornerstone Planning Group first reported a position in ITCI in Q4 2022 and held it in 3 quarters. The position peaked at $1.2K in Q2 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Cornerstone Planning Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Cornerstone Planning Group sold 7 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $890.
  • Cornerstone Planning Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 3 quarters.
  • Cornerstone Planning Group's Intra-Cellular Therapies Inc. position peaked at $1.2K in Q2 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Cornerstone Planning Group's 13F filing for Q1 2025, filed 30 Apr 2025.